Maravai LifeSciences (MRVI)
(Real Time Quote from BATS)
$8.84 USD
+0.37 (4.31%)
Updated Aug 9, 2024 10:30 AM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRVI 8.84 +0.37(4.31%)
Will MRVI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MRVI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRVI
Maravai (MRVI) Advances in RNA Research With New Collaboration
Are Options Traders Betting on a Big Move in Maravai LifeSciences (MRVI) Stock?
MRVI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zynex Inc. (ZYXI) Q3 Earnings Match Estimates
PetIQ (PETQ) Moves 5.7% Higher: Will This Strength Last?
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
Other News for MRVI
Deutsche Bank Reaffirms Their Buy Rating on Maravai Lifesciences Holdings (MRVI)
Maravai Lifesciences: A Strong Buy on Robust Revenue Growth and Strategic Expansion
Stifel Nicolaus Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)
Maravai Lifesciences Holdings (MRVI) Receives a Buy from RBC Capital
Buy Rating Affirmed for Maravai Lifesciences Amid Strong Growth Prospects and Operational Investments